Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 May 1;14(1):27.
doi: 10.1186/1532-429X-14-27.

T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region

Affiliations
Comparative Study

T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region

Nadine Kawel et al. J Cardiovasc Magn Reson. .

Abstract

Background: Myocardial T1 relaxation time (T1 time) and extracellular volume fraction (ECV) are altered in the presence of myocardial fibrosis. The purpose of this study was to evaluate acquisition factors that may result in variation of measured T1 time and ECV including magnetic field strength, cardiac phase and myocardial region.

Methods: 31 study subjects were enrolled and underwent one cardiovascular MR exam at 1.5 T and two exams at 3 T, each on separate days. A Modified Look-Locker Inversion Recovery (MOLLI) sequence was acquired before and 5, 10, 12, 20, 25 and 30 min after administration of 0.15 mmol/kg gadopentetate dimeglumine (Gd-DTPA; Magnevist) at 1.5 T (exam 1). For exam 2, MOLLI sequences were acquired at 3 T both during diastole and systole, before and after administration of Gd-DTPA (0.15 mmol/kg Magnevist).Exam 3 was identical to exam 2 except gadobenate dimeglumine was administered (Gd-BOPTA; 0.1 mmol/kg Multihance). T1 times were measured in myocardium and blood. ECV was calculated by (ΔR1myocardium/ΔR1blood)*(1-hematocrit).

Results: Before gadolinium, T1 times of myocardium and blood were significantly greater at 3 T versus 1.5 T (28% and 31% greater, respectively, p < 0.001); after gadolinium, 3 T values remained greater than those at 1.5 T (14% and 12% greater for myocardium and blood at 3 T with Gd-DTPA, respectively, p < 0.0001 and 18% and 15% greater at 3 T with Gd-BOPTA, respectively, p < 0.0001). However, ECV did not vary significantly with field strength when using the same contrast agent at equimolar dose (p = 0.2). Myocardial T1 time was 1% shorter at systole compared to diastole pre-contrast and 2% shorter at diastole compared to systole post-contrast (p < 0.01). ECV values were greater during diastole compared to systole on average by 0.01 (p < 0.01 to p < 0.0001). ECV was significantly higher for the septum compared to the non-septal myocardium for all three exams (p < 0.0001-0.01) with mean absolute differences of 0.01, 0.004, and 0.07, respectively, for exams 1, 2 and 3.

Conclusion: ECV is similar at field strengths of 1.5 T and 3 T. Due to minor variations in T1 time and ECV during the cardiac cycle and in different myocardial regions, T1 measurements should be obtained at the same cardiac phase and myocardial region in order to obtain consistent results.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intra-individual evaluation of ECV and T1 time at 1.5 T versus 3 T. Effect of field strength for exam 1 (1.5 T Gd-DTPA; black diamond), exam 2 (3 T Gd-DTPA; dark grey square), and exam 3 (3 T Gd-BOPTA; light grey triangle). (A) T1 time of myocardium. (B) T1 time of blood. (C) ECV over time. Results shown as the average for study subjects who completed all three exams (n = 23).
Figure 2
Figure 2
Effect of cardiac phase. Diastolic (black diamond) versus systolic (grey square) comparison of T1 time and ECV for the myocardium (A) and blood pool (B) and ECV (C) over time exemplarily for exam 2 (3 T Gd-DTPA). Results for exam 3 (3 T Gd-BOPTA) were similar (not shown).
Figure 3
Figure 3
Regional variation in T1 time and ECV measurement. Comparison of septal (black diamonds) and non-septal myocardium (grey squares). (A) T1 time of myocardium and (B) ECV exemplarily for exam 2 (3 T Gd-DTPA). Results for exam 3 (3 T Gd-BOPTA) were similar (not shown).
Figure 4
Figure 4
Modified Look-Locker inversion recovery sequence acquired as short axis at mid-cavity 10 minutes after contrast administration in diastole (A) and systole (B). Despite manual motion correction, there are severe artifacts (grade 4) of the inferior, anterior, and anterolateral myocardial walls (arrows, black areas in the myocardium) of the T1 map calculated from images acquired at diastole (A). Good image quality of the corresponding map at systole (B).

References

    1. Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics. 2009;29:89–103. doi: 10.1148/rg.291085052. - DOI - PubMed
    1. Nassenstein K, Breuckmann F, Bucher C, Kaiser G, Konorza T, Schafer L, Konietzka I, de Greiff A, Heusch G, Erbel R, Barkhausen J. How much myocardial damage is necessary to enable detection of focal late gadolinium enhancement at cardiac MR imaging? Radiology. 2008;249:829–835. doi: 10.1148/radiol.2493080457. - DOI - PubMed
    1. Jellis C, Martin J, Narula J, Marwick TH. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56:89–97. doi: 10.1016/j.jacc.2010.02.047. - DOI - PubMed
    1. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903. doi: 10.1016/j.jacc.2010.11.013. - DOI - PMC - PubMed
    1. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574–1580. doi: 10.1016/j.jacc.2008.06.049. - DOI - PubMed

Publication types

MeSH terms